NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Clinical trials for NON-MUSCLE INVASIVE BLADDER NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new NON-MUSCLE INVASIVE BLADDER NEOPLASMS trials appear
Sign up with your email to follow new studies for NON-MUSCLE INVASIVE BLADDER NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted therapy aims to keep bladder cancer from returning
Disease control Recruiting nowThis study tests a new treatment called TAR-210 (erdafitinib) placed directly into the bladder, compared to standard chemotherapy, for people with a high-risk type of bladder cancer that has a specific gene change (FGFR). Participants must have already received BCG therapy. The g…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 16, 2026 22:53 UTC
-
Bladder cancer drug delivered directly to tumor shows promise
Disease control Recruiting nowThis study is testing a new treatment called TAR-210, which delivers the drug erdafitinib directly into the bladder for people with non-muscle-invasive bladder cancer. The goal is to find the best dose and see if it can shrink or eliminate tumors without needing surgery or system…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 16, 2026 22:51 UTC
-
New targeted therapy aims to keep bladder cancer at bay
Disease control Recruiting nowThis study compares a new drug delivery system (TAR-210) that releases erdafitinib directly into the bladder versus standard chemotherapy for people with intermediate-risk non-muscle invasive bladder cancer that has certain genetic changes (FGFR alterations). About 641 participan…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
New bladder cancer treatment TAR-200 tested in Real-World study
Disease control Recruiting nowThis study follows 150 people with early-stage bladder cancer (NMIBC) who are receiving TAR-200 treatment in everyday medical practice. The main goal is to measure how long the cancer stays away after starting TAR-200. Researchers will also track complete responses and side effec…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
New vaccine-like therapy aims to keep bladder cancer from coming back
Disease control Recruiting nowThis study tests whether adding an experimental treatment (V940) to standard BCG therapy helps people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning. About 308 adults will be randomly assigned to get either V940 plus BCG or BCG alone.…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 01, 2026 17:54 UTC
-
New injection targets bladder tumors in early trial
Disease control Recruiting nowThis early-stage study is testing whether a new drug, belzupacap sarotalocan, can be safely injected directly into bladder tumors. The trial involves about 55 people with non-muscle-invasive bladder cancer. Researchers will monitor side effects and check if the treatment helps sh…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE1 • Sponsor: Aura Biosciences • Aim: Disease control
Last updated May 28, 2026 12:03 UTC